IMPORTANT SAFETY INFORMATIONPRESCRIBING INFORMATION

FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated.

Modify FOLOTYN treatment by adjusting or omitting dose as needed1

  • Modified dosing may allow for the possibility of continued treatment in some patients
  • Dose modification may help address:
  • Based on patient tolerance, doses of FOLOTYN may be omitted or reduced. Omitted doses will not be made up at the end of the cycle; once a dose reduction occurs for toxicity, do not re-escalate

Monitor patients for renal function

  • Patients with moderate to severe renal function impairment may be at greater risk for increased exposure and toxicity
  • Monitor patients for renal function and systemic toxicity and adjust dosing accordingly
  • Avoid FOLOTYN use in patients with end stage renal disease including those undergoing dialysis unless the potential benefit justifies the potential risk

References:

  • FOLOTYN Prescribing Information. Allos Therapeutics, Inc. 2012.